Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Duchenne Muscular Dystrophy CardiomyopathyCardiomyopathy, Dilated
Interventions
DRUG

Ifetroban

Weight based, once daily oral ifetroban

DRUG

Placebo

Matching oral placebo

Trial Locations (10)

20010

Children's National Hospital, Washington D.C.

21205

Kennedy Krieger Institute, Baltimore

30341

Children's Healthcare of Atlanta, Atlanta

37232

Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Children's Hospital, Indianapolis

60611

Lurie Children's Hospital, Chicago

63110

Saint. Louis Children's Hospital, St Louis

72202

Arkansas Children's Hospital, Little Rock

90095

Mattel Children's Hospital, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

lead

Cumberland Pharmaceuticals

INDUSTRY

NCT03340675 - Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter